Literature DB >> 31468165

[Determinants of health-related quality of life in systemic lupus erythematosus: a monocentric, retrospective long-term observational study in Germany].

S Vordenbäumen1, R Brinks2, O Sander2, G Chehab2, G Lozitiello-Kiroudis2, H Acar2, J Richter2, R Fischer-Betz2, M Schneider2.   

Abstract

BACKGROUND: Improvement of health-related quality of life (HRQoL) is a prioritized treatment target in systemic lupus erythematosus (SLE). A retrospective chart review of patients with repeated HRQoL measurements from the outpatient department was conducted in order to better understand which factors drive HRQoL in established SLE. Of particular interest was the association between HRQoL and disease activity.
METHODS: The medical outcomes study short form 36 (SF-36), systemic lupus activity measure (SLAM) and routine clinical data of 169 patients (83% female, mean age 40.3 ± 13 years, disease duration 9.4 ± 7 years) over an average of 7.1 ± 4.2 years were available for analysis by linear mixed modelling. Factors associated with the physical component summary (PCS) and mental component summary (MCS) of the SF-36 were assessed. The proportion of HRQoL which could be explained by the variables was estimated by marginal R2 (mR2) and conditional R2 (cR2).
RESULTS: At baseline, SLE patients showed a reduced HRQoL in all subscales of the SF-36 including PCS and MCS with the exception of vitality. A higher PCS over time was significantly associated with concurrent parameters, such as intake of antimalarial drugs, no glucocorticoid use, less fatigue, lower disease activity as well as to the baseline parameters of younger age and higher PCS (mR2 54.7%, cR2 59.9%). A higher MCS was associated with concurrent use of glucocorticoids and a higher baseline MCS (mR2 21.7%, cR2 25.1%).
CONCLUSION: The use of antimalarial drugs and no glucocorticoid intake as well as low current disease activity are modifiable factors associated with a better physical HRQoL. The mental component of HRQoL was poorly represented by conventional parameters and not associated with parameters of disease activity in the present study cohort.

Entities:  

Keywords:  Antimalarial agents; Fatigue; Glucocorticoids; Health-related quality of life; Mental component summary; Physical component summary; SF-36; Systemic lupus erythematosus

Mesh:

Year:  2019        PMID: 31468165     DOI: 10.1007/s00393-019-00691-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  15 in total

1.  2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Authors:  George Bertsias; Dimitrios T Boumpas; Antonis Fanouriakis; Myrto Kostopoulou; Alessia Alunno; Martin Aringer; Ingeborg Bajema; John N Boletis; Ricard Cervera; Andrea Doria; Caroline Gordon; Marcello Govoni; Frédéric Houssiau; David Jayne; Marios Kouloumas; Annegret Kuhn; Janni L Larsen; Kirsten Lerstrøm; Gabriella Moroni; Marta Mosca; Matthias Schneider; Josef S Smolen; Elisabet Svenungsson; Vladimir Tesar; Angela Tincani; Anne Troldborg; Ronald van Vollenhoven; Jörg Wenzel
Journal:  Ann Rheum Dis       Date:  2019-03-29       Impact factor: 19.103

Review 2.  Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology.

Authors:  V Strand; D Gladman; D Isenberg; M Petri; J Smolen; P Tugwell
Journal:  Lupus       Date:  2000       Impact factor: 2.911

3.  A prospective study of factors affecting quality of life in systemic lupus erythematosus.

Authors:  J Thumboo; K Y Fong; S P Chan; K H Leong; P H Feng; S T Thio; M L Boey
Journal:  J Rheumatol       Date:  2000-06       Impact factor: 4.666

4.  Fibromyalgia is a major contributor to quality of life in lupus.

Authors:  D D Gladman; M B Urowitz; J Gough; A MacKinnon
Journal:  J Rheumatol       Date:  1997-11       Impact factor: 4.666

5.  The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus.

Authors:  Ioannis Parodis; Angie H Lopez Benavides; Agneta Zickert; Susanne Pettersson; Sonia Möller; Elisabet Welin Henriksson; Anne Voss; Iva Gunnarsson
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-06       Impact factor: 4.794

6.  Factors influencing the health related quality of life in patients with systemic lupus erythematosus: long-term results (2001--2005) of patients in the German Lupus Erythematosus Self-Help Organization (LULA Study).

Authors:  T Tamayo; R Fischer-Betz; S Beer; B Winkler-Rohlfing; M Schneider
Journal:  Lupus       Date:  2010-09-09       Impact factor: 2.911

7.  Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life?

Authors:  M Jolly; T O Utset
Journal:  Lupus       Date:  2004       Impact factor: 2.911

8.  Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

Authors:  Ronald F van Vollenhoven; Marta Mosca; George Bertsias; David Isenberg; Annegret Kuhn; Kirsten Lerstrøm; Martin Aringer; Hendrika Bootsma; Dimitrios Boumpas; Ian N Bruce; Ricard Cervera; Ann Clarke; Nathalie Costedoat-Chalumeau; László Czirják; Ronald Derksen; Thomas Dörner; Caroline Gordon; Winfried Graninger; Frédéric Houssiau; Murat Inanc; Søren Jacobsen; David Jayne; Anna Jedryka-Goral; Adrian Levitsky; Roger Levy; Xavier Mariette; Eric Morand; Sandra Navarra; Irmgard Neumann; Anisur Rahman; Jozef Rovensky; Josef Smolen; Carlos Vasconcelos; Alexandre Voskuyl; Anne Voss; Helena Zakharova; Asad Zoma; Matthias Schneider
Journal:  Ann Rheum Dis       Date:  2014-04-16       Impact factor: 19.103

9.  Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.

Authors:  Richard Furie; Michelle A Petri; Vibeke Strand; Dafna D Gladman; Z John Zhong; William W Freimuth
Journal:  Lupus Sci Med       Date:  2014-06-26

10.  Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.

Authors:  Chiara Tani; Elena Elefante; Viola Signorini; Dina Zucchi; Valentina Lorenzoni; Linda Carli; Chiara Stagnaro; Francesco Ferro; Marta Mosca
Journal:  RMD Open       Date:  2019-06-11
View more
  2 in total

1.  The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?

Authors:  Anna Kernder; Elena Elefante; Gamal Chehab; Chiara Tani; Marta Mosca; Matthias Schneider
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

2.  Quality of life of patients with rheumatic diseases during the COVID-19 pandemic: The biopsychosocial path.

Authors:  Guillermo A Guaracha-Basáñez; Irazú Contreras-Yáñez; Gabriela Hernández-Molina; Viviana A Estrada-González; Lexli D Pacheco-Santiago; Salvador S Valverde-Hernández; José Roberto Galindo-Donaire; Ingris Peláez-Ballestas; Virginia Pascual-Ramos
Journal:  PLoS One       Date:  2022-01-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.